|
Balance Sheet Cash Flow Statement 3005 1st Ave. Seattle, WA 98121 WA Tel. 206-256-4545 Fax 206-256-0571 |
Type: Public
On the web:
http://www.dendreon.com
Employees:
198
Employee growth: 2.1%
Dendreon wants to boost your immunity from the start. It is developing therapeutic vaccines that goose the body's immune system to help it fight cancer by targeting dendritic cells, which initiate an immune response to disease-causing antigens. Its lead candidate is Provenge, a therapeutic vaccine that targets prostate cancer. Dendreon is also working on a therapeutic vaccine called Neuvenge as a treatment for breast, colon, ovarian, and kidney cancers; and it has research programs investigating cancer-fighting monoclonal antibodies and small molecule drugs. Its partners for its antibody programs include Amgen and Genentech.
Key numbers for fiscal year ending December, 2008:
Sales: $0.1M
One year growth: (85.1%)
Net income: ($71.6)M
Officers:
Chairman: Richard B. Brewer
President, CEO, and Director: Mitchell H. Gold
SVP, CFO, and Treasurer: Gregory T. (Greg) Schiffman
Competitors:
Abbott Labs
Micromet
Northwest Biotherapeutics
